12/8/2022  5:30:15 PM Chg. -0.0070 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
0.5330CHF -1.30% 21,529
Turnover: 11,347.7714
0.5100Bid Size: 206,994 0.5500Ask Size: 40,211 10.36 mill.CHF 0.00% -

Business description

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development of treatments for neuro-ophthalmological, neuromuscular and pulmonary diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and cystic fibrosis (CF). Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein, Serbia and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. Santhera is currently conducting the Phase III SIDEROS trial with Raxone® in patients with Duchenne muscular dystrophy (DMD) in respiratory function decline. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and another product – omigapil – for congenital muscular dystrophy (CMD), both also areas of high unmet medical need.
 

Management board & Supervisory board

CEO
Dario Eklund
Management board
Andrew Smith, Günther Metz, Oliver Strub
Supervisory board
Elmar Schnee, Patrick Vink, Philipp Gutzwiller, Thomas Meier
 

Company data

Name: Santhera Pharmaceuticals Holding AG
Address: Hohenrainstraße 24,CH-4133 Pratteln
Phone: +41-61-9068950
Fax: +41-61-9068951
E-mail: office@santhera.com
Internet: www.santhera.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 87.30%
IPO date: -

Investor relations

Name: Dario Eklund
IR phone: +41-61-9068977
IR Fax: -
IR e-mail: dario.eklund@santhera.com

Main Shareholders

Freefloat
 
87.30%
Idorsia Pharmaceuticals Ltd
 
8.70%
Bertarelli Ernesto, Guichard-Bertarelli Donata and Bertarelli Maria-Iris, Switzerland
 
4.00%